Dachaigh › Lymphoma Cealla B Mòr Sgaoilte › Ohio › Cincinnati
Sgrùdaidhean clionaigeach Lymphoma Cealla B Mòr Sgaoilte ann an Cincinnati, OH
Tha aon sgrùdadh airson Lymphoma Cealla B Mòr Sgaoilte a’ lorg phàirtichean aig làrach ann no faisg air Cincinnati. Fosglaidh e gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A’ fastadhÌre 2
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A’ fastadhSgrùdadh amharc
- Cincinnati Children's Hospital Medical Center, Cincinnati
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
A’ fastadhÌre 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · 15 mìle air falbh
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A’ fastadhÌre 3
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A’ fastadhÌre 2/3
- Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood · 8 mìle air falbh
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A’ fastadhÌre 2
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- Saint Elizabeth Medical Center Edgewood ( Site 0141), Edgewood · 8 mìle air falbh
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
A’ fastadhÌre 1/2
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A’ fastadhÌre 3
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
A’ fastadhÌre 1
- University of Cincinnati Medical Center, Cincinnati
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
A’ fastadhÌre 1
- University of Cincinnati, Cincinnati
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
A’ fastadhÌre 1/2
- University of Cincinnati, Cincinnati
Sgrùdaidhean Lymphoma Cealla B Mòr Sgaoilte ann am bailtean eile
- New York City, NY21 sgrùdaidhean
- Baldwin Park, CA19 sgrùdaidhean
- Chicago, IL18 sgrùdaidhean
- Houston, TX17 sgrùdaidhean
- Los Angeles, CA17 sgrùdaidhean
- Boston, MA16 sgrùdaidhean
- Milwaukee, WI16 sgrùdaidhean
- Nashville, TN15 sgrùdaidhean
- Portland, OR15 sgrùdaidhean
- Philadelphia, PA15 sgrùdaidhean
- Durham, NC14 sgrùdaidhean
- Dallas, TX13 sgrùdaidhean
Sgrùdaidhean eile ann an Cincinnati
- Aillse Sgamhain Neo-chealla-beag35 sgrùdaidhean
- Aillse (gach seòrsa)27 sgrùdaidhean
- Aillse a' bhroilleach25 sgrùdaidhean
- Fàilligeadh a' Chridhe24 sgrùdaidhean
- Aillse colorectal21 sgrùdaidhean
- Leukemia myeloid geur20 sgrùdaidhean
- Ailse metastatach20 sgrùdaidhean
- Cancer Ovarian19 sgrùdaidhean
- Ailseachadh nan Sgamhan19 sgrùdaidhean
- Obesity19 sgrùdaidhean
- Aillse Prostata18 sgrùdaidhean
- Myeloma iomaill17 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.